Insights
In-depth regulation interpretation, authoritative policy insights shared by our experts and specialists.
Hot topic
Q&A
China CDE Q&A on API Filing, Equivalence Evaluation, and Clinical Trial Registration
Nov 01, 2023
Q&A
China CDE Q&A | BE Study, Reference Listed Drug, and Quality & Therapeutic Equivalence Evaluation
Aug 30, 2022
INTERPRETATION
How to Submit Abbreviated New Drug Application (ANDA) for Generic Drugs in China
May 18, 2022